CA3233741A1 - Marqueurs microsatellites - Google Patents
Marqueurs microsatellites Download PDFInfo
- Publication number
- CA3233741A1 CA3233741A1 CA3233741A CA3233741A CA3233741A1 CA 3233741 A1 CA3233741 A1 CA 3233741A1 CA 3233741 A CA3233741 A CA 3233741A CA 3233741 A CA3233741 A CA 3233741A CA 3233741 A1 CA3233741 A1 CA 3233741A1
- Authority
- CA
- Canada
- Prior art keywords
- snp1
- markers
- microsatellite
- msi
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091092878 Microsatellite Proteins 0.000 title claims description 319
- 208000032818 Microsatellite Instability Diseases 0.000 claims abstract description 310
- 238000000034 method Methods 0.000 claims abstract description 142
- 238000012163 sequencing technique Methods 0.000 claims abstract description 63
- 239000003550 marker Substances 0.000 claims description 212
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 claims description 211
- 239000000523 sample Substances 0.000 claims description 145
- 206010028980 Neoplasm Diseases 0.000 claims description 143
- 108020004414 DNA Proteins 0.000 claims description 88
- 239000002773 nucleotide Substances 0.000 claims description 62
- 125000003729 nucleotide group Chemical group 0.000 claims description 62
- 210000000265 leukocyte Anatomy 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 56
- 108091093088 Amplicon Proteins 0.000 claims description 55
- 239000008280 blood Substances 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 44
- 210000005259 peripheral blood Anatomy 0.000 claims description 38
- 239000011886 peripheral blood Substances 0.000 claims description 38
- 108700028369 Alleles Proteins 0.000 claims description 36
- 239000012530 fluid Substances 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 claims description 6
- 201000005027 Lynch syndrome Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 201000005979 Muir-Torre Syndrome Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 108
- 230000033607 mismatch repair Effects 0.000 description 95
- 238000003556 assay Methods 0.000 description 60
- 238000004458 analytical method Methods 0.000 description 55
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 44
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 44
- 238000007403 mPCR Methods 0.000 description 39
- 230000002950 deficient Effects 0.000 description 33
- 210000004602 germ cell Anatomy 0.000 description 31
- 230000035772 mutation Effects 0.000 description 31
- 230000003321 amplification Effects 0.000 description 27
- 238000003199 nucleic acid amplification method Methods 0.000 description 27
- 238000000926 separation method Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 20
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 19
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 19
- 238000001514 detection method Methods 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 16
- 108091092584 GDNA Proteins 0.000 description 15
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 13
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 13
- 238000013103 analytical ultracentrifugation Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000009826 distribution Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101150061338 mmr gene Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 238000000585 Mann–Whitney U test Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001613 neoplastic effect Effects 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 6
- 206010066476 Haematological malignancy Diseases 0.000 description 6
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 6
- 229910015837 MSH2 Inorganic materials 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000012070 whole genome sequencing analysis Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 4
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000012268 genome sequencing Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028617 response to DNA damage stimulus Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000013077 scoring method Methods 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 101710041373 KIAA0753 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100023399 Protein moonraker Human genes 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000001861 endoscopic biopsy Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091035233 repetitive DNA sequence Proteins 0.000 description 3
- 102000053632 repetitive DNA sequence Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 2
- 101100298222 Caenorhabditis elegans pot-1 gene Proteins 0.000 description 2
- 101100298225 Caenorhabditis elegans pot-2 gene Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 2
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 2
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000013101 initial test Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100004287 Caenorhabditis elegans best-6 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000016311 Freckling Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000881230 Homo sapiens Sprouty-related, EVH1 domain-containing protein 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- -1 PCR reaction mixes Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040868 Skin hypopigmentation Diseases 0.000 description 1
- 102100037614 Sprouty-related, EVH1 domain-containing protein 1 Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000310 mutation rate increase Toxicity 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 208000001095 pilomatrixoma Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220065649 rs869320619 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne de nouveaux procédés pour évaluer des niveaux d'instabilité de microsatellite dans un échantillon et pour évaluer l'importance biologique de variations de séquence identifiées dans un échantillon au cours du séquençage. L'invention concerne en outre l'utilisation de nouveaux marqueurs d'instabilité de microsatellite pour évaluer des niveaux d'instabilité de microsatellite dans un échantillon et pour évaluer l'importance biologique de variations de séquence identifiées dans un échantillon pendant le séquençage. Des kits correspondants sont également décrits.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2114136.1A GB202114136D0 (en) | 2021-10-01 | 2021-10-01 | Microsatellite markers |
GB2114136.1 | 2021-10-01 | ||
PCT/GB2022/052500 WO2023052795A1 (fr) | 2021-10-01 | 2022-10-03 | Marqueurs microsatellites |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3233741A1 true CA3233741A1 (fr) | 2023-04-06 |
Family
ID=78497788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3233741A Pending CA3233741A1 (fr) | 2021-10-01 | 2022-10-03 | Marqueurs microsatellites |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20240095538A (fr) |
CN (1) | CN118043483A (fr) |
AU (1) | AU2022357505A1 (fr) |
CA (1) | CA3233741A1 (fr) |
GB (1) | GB202114136D0 (fr) |
WO (1) | WO2023052795A1 (fr) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201614474D0 (en) | 2016-08-24 | 2016-10-05 | Univ Of Newcastle Upon Tyne The | Methods of identifying microsatellite instability |
EP4400601A2 (fr) * | 2017-07-12 | 2024-07-17 | Institut Curie | Procédé de détection d'une mutation dans une séquence microsatellite |
CA3132219A1 (fr) * | 2019-03-06 | 2020-09-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Procede de diagnostic du syndrome cmmrd |
WO2021019197A1 (fr) | 2019-07-31 | 2021-02-04 | University Of Newcastle Upon Tyne | Procédés d'identification d'instabilité de micro-satellite |
-
2021
- 2021-10-01 GB GBGB2114136.1A patent/GB202114136D0/en not_active Ceased
-
2022
- 2022-10-03 CN CN202280066807.8A patent/CN118043483A/zh active Pending
- 2022-10-03 CA CA3233741A patent/CA3233741A1/fr active Pending
- 2022-10-03 WO PCT/GB2022/052500 patent/WO2023052795A1/fr active Application Filing
- 2022-10-03 KR KR1020247014766A patent/KR20240095538A/ko unknown
- 2022-10-03 AU AU2022357505A patent/AU2022357505A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB202114136D0 (en) | 2021-11-17 |
AU2022357505A1 (en) | 2024-05-02 |
CN118043483A (zh) | 2024-05-14 |
KR20240095538A (ko) | 2024-06-25 |
WO2023052795A1 (fr) | 2023-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106755501B (zh) | 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法 | |
KR102648965B1 (ko) | 간세포 암종 검출 | |
EP3377647B1 (fr) | Acides nucléiques et procédés de détection de l'état de méthylation | |
WO2018090298A2 (fr) | Systèmes et procédés de surveillance d'évolution tumorale à vie | |
AU2017316709B2 (en) | Methods of identifying microsatellite instability | |
US11384401B2 (en) | Detecting gastrointestinal neoplasms | |
KR20150082228A (ko) | 혈장으로부터 태아 또는 종양 메틸롬의 비침습적 결정 | |
EP3034624A1 (fr) | Procédé pour le pronostic d'un carcinome hépatocellulaire | |
WO2017112738A1 (fr) | Procédés pour mesurer l'instabilité microsatellitaire | |
JP2024020392A (ja) | 特定の遺伝子のcpgメチル化変化を利用した肝癌診断用組成物およびその使用 | |
KR102275752B1 (ko) | 결정적 제한 부위 전체 게놈 증폭에 의해 수득된 dna 서열의 라이브러리의 게놈 무결성 및/또는 품질을 측정하기 위한 방법 및 키트 | |
Zhan et al. | DNA methylation detection methods used in colorectal cancer | |
US10155993B2 (en) | Method or kit for determining lung cancer development | |
US20140242583A1 (en) | Assays, methods and compositions for diagnosing cancer | |
KR102236717B1 (ko) | 조혈모세포 이식 후 혈액암 예후 예측을 위한 정보 제공 방법 | |
CA3233741A1 (fr) | Marqueurs microsatellites | |
CN111440866B (zh) | Dusp3基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用 | |
CN111440865B (zh) | Fat3基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用 | |
CN111440864B (zh) | Tle4基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用 | |
US11702692B2 (en) | Method of treatment of disease and method for quantifying the level of minimal residual disease in a subject | |
Lung | Identification of candidate genes predisposing to familial colorectal cancer by germline whole exome sequencing | |
WO2020007951A1 (fr) | Méthode épigénétique pour détecter et faire la distinction entre des syndromes ipex et des syndromes de type ipex, en particulier chez les nouveau-nés | |
Johansson | Looking through the noise |